Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta

Neurobiology of Disease

Volumn 39, Issue 3, 2010, Pages 301-310

  Vasilevko, Vitaly ^a   Pop, Viorela ^a,b   Kim, Hyun Jin ^a   Saing, Tommy ^a   Glabe, Charles C ^a   Milton, Saskia ^a   Barrett, Edward G ^c   Cotman, Carl W ^a,b   Cribbs, David H ^a,b   Head, Elizabeth ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Aged beagles; Alzheimer's disease; Amyloid beta; Conformational antibodies; Immunotherapy; Large animal model

Indexed keywords

ALUMINUM HYDROXIDE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42];

ACTIVE IMMUNIZATION; AGED; AMINO TERMINAL SEQUENCE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOG; EPITOPE MAPPING; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; TH2 CELL;

EID: 77954957153     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.04.014     Document Type: Article

References (58)

1. Anguiano M., et al. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 2002, 41:11338-11343.
2. Asuni A.A., et al. Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur. J. Neurosci. 2006, 24:2530-2542.
3. Bard F., et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl Acad. Sci. USA 2003, 100:2023-2028.
4. Bayer A.J., et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005, 64:94-101.
5. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
6. Britschgi M., et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc. Natl Acad. Sci. USA 2009, 106:12145-12150.
7. Cribbs D.H., et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 2003, 15:505-514.
8. Cummings B.J., et al. The canine as an animal model of human aging and dementia. Neurobiol. Aging 1996, 17:259-268.
9. Durham S.R., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J. Med. 1999, 341:468-475.
10. Finkelman F.D., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 1990, 8:303-333.
11. German A.J., et al. Measurement of IgG, IgM and IgA concentrations in canine serum, saliva, tears and bile. Vet. Immunol. Immunopathol. 1998, 64:107-121.
12. Gevorkian G., et al. Mimotopes of conformational epitopes in fibrillar beta-amyloid. J. Neuroimmunol. 2004, 156:10-20.
13. Gilman S., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
14. Golde T.E., et al. Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. Curr. Alzheimer Res. 2006, 3:421-430.
15. Gordon D.M. Use of novel adjuvants and delivery systems to improve the humoral and cellular immune response to malaria vaccine candidate antigens. Vaccine 1993, 11:591-593.
16. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
17. Head E., et al. Visual-discrimination learning ability and beta-amyloid accumulation in the dog. Neurobiol. Aging 1998, 19:415-425.
18. Head E., et al. Region-specific age at onset of beta-amyloid in dogs. Neurobiol. Aging 2000, 21:89-96.
19. Head E., et al. Immunization with fibrillar Abeta(1-42) in young and aged canines: antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine 2006, 24:2824-2834.
20. Head E., et al. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J. Neurosci. 2008, 28:3555-3566.
21. Hock C., et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 2002, 8:1270-1275.
22. Hock C., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554.
23. Holmes C., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
24. Hsiao K., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
25. Janus C., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
26. Kayed R., et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007, 2:18.
27. Kirkness E.F., et al. The dog genome: survey sequencing and comparative analysis. Science 2003, 301:1898-1903.
28. Kool M., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 2008, 205:869-882.
29. Lee M., et al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann. Neurol. 2005, 58:430-435.
30. Lemere C.A., et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am. J. Pathol. 2004, 165:283-297.
31. Lesne S., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
32. Lin C.Y., et al. Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice. Diabetes 2007, 56:1324-1332.
33. Lue L.F., et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 1999, 155:853-862.
34. McLaurin J., et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 2002, 8:1263-1269.
35. Meyer-Luehmann M., et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006, 313:1781-1784.
36. Milgram N.W., et al. Cognitive functions and aging in the dog: acquisition of nonspatial visual tasks. Behav. Neurosci. 1994, 108:57-68.
37. Milgram N.W., et al. Landmark discrimination learning in the dog: effects of age, an antioxidant fortified food, and cognitive strategy. Neurosci. Biobehav. Rev. 2002, 26:679-695.
38. Mirra S.S., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
39. Morgan D., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
40. Mucke L., et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
41. Necula M., et al. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 2007, 46:8850-8860.
42. Orgogozo J.M., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
43. Patel M., et al. Sequence of the dog immunoglobulin alpha and epsilon constant region genes. Immunogenetics 1995, 41:282-286.
44. Peters I.R., et al. Measurement of immunoglobulin concentrations in the feces of healthy dogs. Clin. Diagn. Lab. Immunol. 2004, 11:841-848.
45. Petrushina I., et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J. Neurosci. 2007, 27:12721-12731.
46. Pride M., et al. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis. 2008, 5:194-196.
47. Purkerson J., Isakson P. A two-signal model for regulation of immunoglobulin isotype switching. FASEB J. 1992, 6:3245-3252.
48. Rodriguez V., et al. The IgG isotypes of specific antibodies in patients with American cutaneous leishmaniasis; relationship to the cell-mediated immune response. Parasite Immunol. 1996, 18:341-345.
49. Rogers K.A., et al. Molecular characterization of immunoglobulin D in mammals: immunoglobulin heavy constant delta genes in dogs, chimpanzees and four old world monkey species. Immunology 2006, 118:88-100.
50. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 2002, 3:824-828.
51. Schenk D., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
52. Seabrook T.J., et al. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol. Aging 2007, 28:813-823.
53. Selkoe D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 1996, 271:18295-18298.
54. Selkoe D.J. Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease. Nutr. Rev. 2007, 65:S239-S243.
55. Selkoe D.J., Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 2003, 43:545-584.
56. Tang L., et al. Cloning and characterization of cDNAs encoding four different canine immunoglobulin gamma chains. Vet. Immunol. Immunopathol. 2001, 80:259-270.
57. Walsh D.M., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
58. Walsh D.M., et al. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 2002, 30:552-557.